AstraZeneca (AZN) 2025 Earnings Call Presentation

AstraZeneca Ambition & Strategy - AstraZeneca aims to achieve $80 billion in total revenue by 2030, driven by its existing portfolio and the launch of new medicines [7, 8] - The 2030 total revenue ambition is not dependent on future mergers and acquisitions [8] - Cardiometabolic diseases are a key area of focus, with the goal of transforming care and addressing unmet needs [17] Baxdrostat Clinical Trial (BaxHTN) Results - The Phase III BaxHTN trial demonstrated that baxdrostat, at 1mg and 2mg doses, led to placebo-adjusted reductions in seated systolic blood pressure (SBP) of 8.7 mmHg and 9.8 mmHg respectively after 12 weeks in patients with uncontrolled or resistant hypertension [63] - In the BaxHTN trial, 73% of participants had resistant hypertension, while 27% had uncontrolled hypertension [43] - Serum aldosterone concentration decreased from baseline to Week 12 with baxdrostat 1mg by 60% (from 7.9 to 3.2 ng/dL) and with baxdrostat 2mg by 65% (from 7.2 to 2.5 ng/dL) [55] - In the BaxHTN trial, rates of confirmed serum potassium >6.0 mmol/L were low, at 1% in both baxdrostat groups [63] Baxdrostat Market Opportunity - Baxdrostat has a potential of $5 billion+ across monotherapy and combination opportunities [69] - There are over 75 million uncontrolled 2L+ hypertension patients ex-US and over 20 million in the US [68]